Cardiac Science Announces Third Quart...(----- ---- ----- ---- ...),Health

Date:11/9/2009

----- ---- ----- ---- Total cost of revenues 38,789 99.8% 27,887 51.6% ------ ---- ------ ---- Gross Profit: Products (1,048) -3.0% 24,588 49.8% Service 1,143 27.0% 1,531 33.1% ----- ---- ----- ---- Gross profit 95 0.2% 26,119 48.4% --- --- ------ ---- Operating Expenses: Research and development 4,270 11.0% 4,103 7.6% Sales and marketing 11,923 30.7% 12,934 23.9% General and administrative 6,571 16.9% 5,096 9.4% ----- ---- ----- --- Total operating expenses 22,764 58.5% 22,133 41.0% ------ ---- ------ ---- Operating income (loss) (22,669) -58.3% 3,986 7.4% ------- ----- ----- --- Other Income: Interest income 23 0.1% 156 0.3% Other income, net 158 0.4% 20 0.0% --- --- -- --- Total other income 181 0.5% 176 0.3% --- --- --- --- Income (loss) before income tax expense: (22,488) -57.8% 4,162 7.7% Income tax expense (43,923) -113.0% (1,598) -3.0% ------- ------ ------ ---- Net income (loss) (66,411) -170.8% 2,564 4.7% Less:
'/>"/>

SOURCE Cardiac Science Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery